111 related articles for article (PubMed ID: 35902040)
1. Therapeutic restoring p53 function with small molecule for oncogene-driven non-small cell lung cancer by targeting serine 392 phosphorylation.
Li L; Li P; Ma X; Zeng S; Peng Y; Zhang G
Biochem Pharmacol; 2022 Sep; 203():115188. PubMed ID: 35902040
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule MX-C2/3 suppresses non-small cell lung cancer progression via p53 activation.
Li L; Du W; Wang H; Zhao Y; Huang Z; Peng Y; Zeng S; Zhang G
Chem Biol Interact; 2022 Oct; 366():110142. PubMed ID: 36058261
[TBL] [Abstract][Full Text] [Related]
3. A Novel Naphthalimide Compound Restores p53 Function in Non-small Cell Lung Cancer by Reorganizing the Bak·Bcl-xl Complex and Triggering Transcriptional Regulation.
Zhang G; An Y; Lu X; Zhong H; Zhu Y; Wu Y; Ma F; Yang J; Liu Y; Zhou Z; Peng Y; Chen Z
J Biol Chem; 2016 Feb; 291(8):4211-25. PubMed ID: 26668309
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
6. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo.
Katiyar SK; Meeran SM; Katiyar N; Akhtar S
Mol Carcinog; 2009 Jan; 48(1):24-37. PubMed ID: 18459128
[TBL] [Abstract][Full Text] [Related]
7. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
8. Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways.
Liu Z; Fu Q; Wang Y; Cui L; Zhang W; Teng Y; Yu P
Biomed Pharmacother; 2021 Feb; 134():111144. PubMed ID: 33360044
[TBL] [Abstract][Full Text] [Related]
9. Green tea-derived theabrownin suppresses human non-small cell lung carcinoma in xenograft model through activation of not only p53 signaling but also MAPK/JNK signaling pathway.
Xiao X; Guo L; Dai W; Yan B; Zhang J; Yuan Q; Zhou L; Shan L; Efferth T
J Ethnopharmacol; 2022 Jun; 291():115167. PubMed ID: 35271947
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells.
Rathos MJ; Khanwalkar H; Joshi K; Manohar SM; Joshi KS
BMC Cancer; 2013 Jan; 13():29. PubMed ID: 23343191
[TBL] [Abstract][Full Text] [Related]
11. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
12. Phthalazino[1,2-b]quinazolinones as p53 Activators: Cell Cycle Arrest, Apoptotic Response and Bak-Bcl-xl Complex Reorganization in Bladder Cancer Cells.
Zhang GH; Yuan JM; Qian G; Gu CX; Wei K; Mo DL; Qin JK; Peng Y; Zhou ZP; Pan CX; Su GF
J Med Chem; 2017 Aug; 60(16):6853-6866. PubMed ID: 28745887
[TBL] [Abstract][Full Text] [Related]
13. Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer.
Freire Boullosa L; Van Loenhout J; Flieswasser T; De Waele J; Hermans C; Lambrechts H; Cuypers B; Laukens K; Bartholomeus E; Siozopoulou V; De Vos WH; Peeters M; Smits ELJ; Deben C
Redox Biol; 2021 Jun; 42():101949. PubMed ID: 33812801
[TBL] [Abstract][Full Text] [Related]
14. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
[TBL] [Abstract][Full Text] [Related]
15. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Small Molecule Bak Activator for Lung Cancer Therapy.
Park D; Anisuzzaman ASM; Magis AT; Chen G; Xie M; Zhang G; Behera M; Sica GL; Ramalingam SS; Owonikoko TK; Deng X
Theranostics; 2021; 11(17):8500-8516. PubMed ID: 34373755
[No Abstract] [Full Text] [Related]
17. Xanthatin triggers Chk1-mediated DNA damage response and destabilizes Cdc25C via lysosomal degradation in lung cancer cells.
Tao L; Cao Y; Wei Z; Jia Q; Yu S; Zhong J; Wang A; Woodgett JR; Lu Y
Toxicol Appl Pharmacol; 2017 Dec; 337():85-94. PubMed ID: 29074359
[TBL] [Abstract][Full Text] [Related]
18. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer.
Rho JK; Choi YJ; Ryoo BY; Na II; Yang SH; Kim CH; Lee JC
Cancer Res; 2007 Feb; 67(3):1163-9. PubMed ID: 17283151
[TBL] [Abstract][Full Text] [Related]
19. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
[TBL] [Abstract][Full Text] [Related]
20. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
